Home » Stocks » APRE

Aprea Therapeutics, Inc. (APRE)

Stock Price: $5.51 USD 0.11 (1.94%)
Updated Jan 20, 2021 1:22 PM EST - Market open
Market Cap 110.91M
Revenue (ttm) n/a
Net Income (ttm) -51.16M
Shares Out 21.19M
EPS (ttm) -26.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $5.51
Previous Close $5.40
Change ($) 0.11
Change (%) 1.94%
Day's Open 5.40
Day's Range 5.31 - 5.52
Day's Volume 936,278
52-Week Range 4.73 - 41.09

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactiva...

Zacks Investment Research - 3 weeks ago

Aprea (APRE) down as late-stage study on lead candidate, eprenetapopt, combined with azacitidine (AZA) versus AZA alone in TP53 mutant myelodysplastic syndromes (MDS) fails.

24/7 Wall Street - 3 weeks ago

Aprea Therapeutics Inc. (NASDAQ: APRE) stock was absolutely crushed to start out the week after the company announced results from its late-stage trial evaluating the safety and efficacy of it...

GlobeNewsWire - 3 weeks ago

BOSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactiva...

GlobeNewsWire - 1 month ago

BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactiva...

The Motley Fool - 1 month ago

Aprea Therapeutics, Viking Therapeutics, and Vaxart could all generate life-changing returns for early shareholders.

Other stocks mentioned: VKTX, VXRT
GlobeNewsWire - 2 months ago

BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactiva...

GlobeNewsWire - 2 months ago

BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactiva...

GlobeNewsWire - 2 months ago

BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate...

GlobeNewsWire - 3 months ago

BOSTON, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate...

GlobeNewsWire - 3 months ago

BOSTON, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics th...

GlobeNewsWire - 4 months ago

BOSTON, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics...

GlobeNewsWire - 4 months ago

BOSTON, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that react...

GlobeNewsWire - 5 months ago

BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reacti...

Seeking Alpha - 5 months ago

Aprea Therapeutics Cancer Therapy Platform Is Promising

GlobeNewsWire - 6 months ago

Karolinska Development’s portfolio company Aprea Therapeutics expands clinical trial of eprenetapopt for TP53 mutant Acute Myeloid Leukemia

GlobeNewsWire - 6 months ago

BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reacti...

Zacks Investment Research - 6 months ago

Aprea Therapeutics (APRE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

The Motley Fool - 6 months ago

These companies offer promising pipelines that could deliver in the long term.

Other stocks mentioned: ATRA
GlobeNewsWire - 6 months ago

BOSTON, June 29, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics ...

GlobeNewsWire - 7 months ago

BOSTON, June 12, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reacti...

Zacks Investment Research - 7 months ago

Aprea Therapeutics (APRE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

The Motley Fool - 7 months ago

Here's why this biotech company with a promising treatment for a rare blood disorder is a solid buy.

GlobeNewsWire - 7 months ago

BOSTON, June 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reacti...

GlobeNewsWire - 8 months ago

BOSTON, May 15, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactiv...

Zacks Investment Research - 8 months ago

Aprea Therapeutics (APRE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 9 months ago

BOSTON, April 06, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactiv...

GlobeNewsWire - 9 months ago

BOSTON, March 26, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that react...

The Motley Fool - 10 months ago

While IPOs allow companies to tap into capital markets, going public provides liquidity to early-stage investors seeking to unload stock positions.

Other stocks mentioned: FREQ, VIE, VIR
The Motley Fool - 11 months ago

The drug candidate is in phase 3 trials as a treatment of myelodysplastic syndrome (MDS), which often leads to blood and bone marrow cancers.

GlobeNewsWire - 11 months ago

BOSTON, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reacti...

The Motley Fool - 1 year ago

Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.

Other stocks mentioned: APLT, BNTX, GKOS, INMD, KRTX, NXTC, PLMR, RAPT, TPTX
GlobeNewsWire - 1 year ago

BOSTON, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Lead investigators from US and French Phase Ib/II clinical trials of APR-246 and Azacitidine (AZA) in patients with TP53 mutant MDS and AML, present...

GlobeNewsWire - 1 year ago

BOSTON, Dec. 09, 2019 (GLOBE NEWSWIRE) --  Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that react...

Benzinga - 1 year ago

Aprea Therapeutics Inc (NASDAQ: APRE) shares cooled a bit Tuesday after getting off to a hot start on the market following an Oct.

GlobeNewsWire - 1 year ago

BOSTON, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reacti...

The Motley Fool - 1 year ago

Three biotech companies successfully completed IPOs last week. Would investors have been better off buying shares in the open market?

Other stocks mentioned: FREQ, VIE
Benzinga - 1 year ago

Aprea Therapeutics, Inc. (NASDAQ: APRE) made its public debut Thursday morning, opening at $15.46 after being priced at $15 per share.

Market Watch - 1 year ago

Aprea Therapeutics Inc. APRE, +11.00% got off to a positive start as a public company Thursday, as the first trade of the cancer treatment developer's stock was 3.1% above its $15 initial publ...

About APRE

Aprea Therapeutics, a biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate is APR-246, a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. The company was founded in 2006 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
IPO Date
Oct 3, 2019
CEO
Christian S. Schade
Employees
13
Stock Exchange
NASDAQ
Ticker Symbol
APRE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for APRE stock is "Hold." The 12-month stock price forecast is 11.33, which is an increase of 105.81% from the latest price.

Price Target
$11.33
(105.81% upside)
Analyst Consensus: Hold